低危与中危前列腺癌:SBRT与LDR近距离放疗的生化控制及毒性比较
本研究回顾2010至2018年接受SBRT或LDR近距离放疗的低危与中危前列腺癌患者,比较生化控制与毒性。LDR组219例、SBRT组118例,中位随访4.3年;LDR组早期AUA与EPIC评分升高更明显,晚期3级泌尿生殖毒性无显著差异,但SBRT晚期3级胃肠道毒性更高。
核心结论
- SBRT与LDR在5年生化控制和泌尿生殖毒性方面相似,SBRT胃肠道毒性略高,LDR早期AUA与EPIC评分更高。
研究设计与样本
- 回顾性队列研究,纳入2010至2018年接受根治性SBRT或LDR的低危与中危前列腺癌患者,LDR组219例、SBRT组118例,中位随访4.3年(四分位距3.1-6.1)。
关键数值与推荐
- LDR方案为单次125.0 Gy;SBRT方案为42.5 Gy分5次。
- 生化失败采用Phoenix定义。
临床怎么用
- 低危与中危前列腺癌选择SBRT或LDR时,可预期相似的5年生化控制和泌尿生殖毒性。
- 需关注LDR早期泌尿症状评分升高更明显,以及SBRT晚期3级胃肠道毒性略高。
局限性
- 回顾性研究设计,样本量有限(LDR 219例、SBRT 118例),中位随访4.3年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Low-dose-rate (LDR) brachytherapy and stereotactic body radiation therapy (SBRT) have both shown acceptable outcomes in the treatment of low- and intermediate-risk prostate cancer. Minimal data have been published directly comparing rates of biochemical control and toxicity with these 2 modalities. We hypothesize that LDR and SBRT will provide similar rates of biochemical control. METHODS AND MATERIALS: All low- and intermediate-risk patients with prostate cancer treated definitively with SBRT or LDR between 2010 and 2018 were captured. Phoenix definition was used for biochemical failure. Independent t tests were used to compare baseline characteristics, and repeated measure analysis of variance test was used to compare American Urologic Association (AUA) and the Expanded Prostate Cancer Index Composite (EPIC) scores between treatment arms over time. Biochemical control was estimated using the Kaplan-Meier method. Differences in acute and late toxicity were assessed via Pearson χ2. RESULTS: In the study, 219 and 118 patients were treated with LDR and SBRT. Median follow-up was 4.3 years (interquartile range, 3.1-6.1). All patients treated with LDR received 125.0 Gy in a single fraction. SBRT consisted of 42.5 Gy in 5 fractions. Five-year biochemical control for LDR versus SBRT was 91.6% versus 97.6% (P = .108). LDR patients had a larger increase in mean AUA scores at 1 month (17.2 vs 10.3, P < .001) and 3 months posttreatment (14.0 vs 9.7, P < .001), and in mean EPIC scores at 1 month (15.7 vs 13.8, P < .001). There was no significant difference between LDR and SBRT in late grade 3 genitourinary toxicity (0.9% vs 2.5%, P = .238); however, LDR had lower rates of late grade 3 gastrointestinal toxicity (0.0% vs 2.5%, P = .018). CONCLUSIONS: Our data show similar biochemical control and genitourinary toxicity rates at 5 years for both SBRT and LDR, with slightly higher gastrointestinal toxicity with SBRT and higher AUA and EPIC scores with LDR.
引用
- Gogineni E, Rana Z, Soberman D, et al. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 33171199. doi:10.1016/j.ijrobp.2020.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。